The pharmaceutical industry is currently behind other brick-and-mortar industries in terms of e-business growth, but is moving rapidly to accelerate progress.
In a global industry analysis conducted by KPMG International, a professional services organization, the pharmaceutical industry is currently behind other brick-and-mortar industries in terms of e-business growth, but is moving rapidly to accelerate progress.
The findings are reported in the KPMG study "The e-business value chain: Winning strategies in seven global industries," which was conducted by the Economist Intelligence Unit in cooperation with KPMG in June, 2000.
"The pharmaceutical industry was last out of the gate in adopting e-business early on, because the benefits just weren't obvious," said John Morris, European chair for chemicals and pharmaceuticals. "But that's changed because of increasing pressures."
According to Morris, these pressures include the need to search for new ways to bring drugs to the market faster, the need to trim costs and the need to market products more precisely and cheaply. Pharmaceutical executives are feeling shareholder pressure as well, and to a higher degree than most other industries, according to the survey respondents.
As an indicator that the pharmaceutical industry is getting more aggressive with e-business, 82% of pharmaceutical companies expect in 18 months to offer at least limited transactions through their Web sites, up from the current 21%. During this period, pharmaceutical executives project on-line sales to increase from 3% to 14%.
Industry executives predict significant progress in the area of supply chain management with respect to on-line exchanges. For example, use of industry-specific on-line exchanges for supply chain management will increase from 6% of companies to 49% in the next 18 months, along with an expected increase in multi-industry exchanges from 12% to 36%. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.